AnalysisBusiness · Deals & Funding

Grindr buys Freddie for $250 million to put PrEP inside the app

The dating app is becoming an HIV prevention provider. For clinicians, the questions are continuity, monitoring and trust.

Oct 5, 2026By longevitydocs™ editors
The Grindr and Freddie app logos on two phone screens
Image: longevitydocs™ News

Grindr has agreed to acquire Freddie, a telehealth provider of PrEP and HIV prevention care, for $250 million: $190 million in cash and $60 million in stock, plus up to $70 million more if Freddie hits 2027 performance targets. The deal was announced on September 30 and is expected to close in the fourth quarter of 2026.

Freddie is the consumer brand of PurposeMed, founded in Canada in 2020. It offers PrEP, HIV testing, prescriptions and medication delivery in all 50 US states and five Canadian provinces, and says it has served more than 55,000 patients. It projects more than $80 million in revenue and more than $10 million in adjusted EBITDA this year.

What changes

Grindr reports 16 million average monthly active users. The plan is to let them learn about PrEP, meet a Freddie clinician, arrange testing and receive a prescription inside the app, then manage refills, reminders and messages with their care team. Grindr says participation is voluntary. Freddie will sit alongside Woodwork, Grindr's existing performance-medication service.

The stated goal is to connect 10 million LGBTQ+ people to HIV prevention through the app by 2028. “The challenge is connecting people to PrEP and helping them stay on it,” said Grindr CEO George Arison.

Grindr CEO George Arison and Freddie CEO Dr. Husein Moloo at a table with a signed agreement on a tablet
Grindr CEO George Arison (left) and Freddie CEO Dr. Husein Moloo. Photo: George Arison via LinkedIn

Why it matters

The access gap is real. CDC estimated that in 2022 only 36% of the 1.2 million people in the US who could benefit from PrEP were prescribed it. Efficacy is not the problem: taken as prescribed, PrEP reduces the risk of getting HIV from sex by about 99%. Freddie estimates that its patients' PrEP use prevents about 385 new HIV transmissions a year. That figure is the company's own estimate.

Starting PrEP is the easy half. Staying on it requires ongoing HIV testing, STI screening and, for oral regimens, kidney monitoring. Twice-yearly injectable lenacapavir, approved by the FDA in June 2025, changes the adherence equation. The announcement does not say which regimens Freddie will offer inside Grindr.

The strategy

This is a bet on patient acquisition and sustained engagement. Telehealth companies spend heavily to find patients and then lose many of them. Grindr already has 16 million people opening its app every month. Turning that active user base into a high-retention digital health network is a smart growth strategy, and it makes preventive care more accessible to the people who need it most.

Data privacy and trust will be essential. Prescriptions, test results and refill reminders will now live inside a dating app, and users will need to be confident that their health information stays separate and protected.

What it means for physicians

  • Expect more patients on app-based PrEP. Ask who orders their HIV tests, STI screening and kidney labs, and request the records.
  • The front door to prevention is moving to apps patients already open every day. Physicians who want to stay in the loop need a way to coordinate with those platforms.
  • Ask patients whether they were offered long-acting PrEP. Adherence, not efficacy, is where most PrEP fails.
By
longevitydocs™ editors
Published
Oct 5, 2026
Sources
Primary source
Grindr press release, September 30, 2026 (Business Wire)
CDC, Expanding PrEP coverage in the United States (2022 data)

Share this article

WRITTEN BYlongevitydocs™ editorsCurated by the longevitydocs™ editorial team from The Sunday Newsletter

Read more

All stories
FROM THE NETWORK

The Buzz in the Chat

What physicians are discussing across the longevitydocs™ network.

Explore the discussion →